Trial Profile

A Randomized, Double-blind, Parallel, Vehicle Controlled, Repeat Dose Comparative Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ORTD-1 in Rheumatoid Arthritis Patients With Mild Disease Managed With DMARDs

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ORYN 1001 (Primary) ; Azathioprine; Hydroxychloroquine; Leflunomide; Methotrexate; Sulfasalazine
Indications Rheumatoid arthritis
Focus Adverse reactions
Sponsors Oryn Therapeutics

15 Oct 2021 Status changed from recruiting to completed.
26 Mar 2021 Planned End Date changed from 1 Apr 2021 to 1 Sep 2021.
26 Mar 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Sep 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com